2283335-13-5
2283335-13-5 结构式
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2025/12/22 | HY-P0133A | (Arg)9 TFA (Arg)9 TFA | 2283335-13-5 | 1mg | 560元 |
| 2025/12/22 | HY-P0133A | (Arg)9 TFA (Arg)9 TFA | 2283335-13-5 | 5mg | 1250元 |
| 2025/12/22 | HY-P0133A | (Arg)9 TFA (Arg)9 TFA | 2283335-13-5 | 10 mg | 1980元 |
常见问题列表
IC50: 0.78 μM (neuroprotection).
Poly-arginine (e.g. (Arg)9) and arginine-rich peptides (e.g. TAT, penetratin), which belong to a class of peptides with cell-penetrating properties are neuroprotective. (Arg)9 provides significant neuroprotection in a dose–response manner following glutamic acid exposure (IC 50 =0.78 μM). Following kainic acid exposure, (Arg)9 is neuroprotective, but less effective than in the glutamic acid model (IC 50 =0.81 μM). (Arg)9 also shows neuroprotection following in vitro ischemia (IC 50 =6 μM).
(Arg)9) (D-isoform) is neuroprotective in rat stroke models. (Arg)9) is highly neuroprotective, with efficacy increasing with increasing arginine content, has the capacity to reduce glutamic acid-induced neuronal calcium influx and requires heparan sulfate preotoglycan-mediated endocytosis to induce a neuroprotective effect. (Arg)9) (D-isoform) administered intravenously at a dose of 1000 nmol/kg 30 min after permanent middle cerebral artery occlusion (MCAO) reduces infarct volume.